开发一种针对乳腺癌的多种应用的抗EphB4单克隆抗体
Ren Nanamiya1, Hiroyuki Suzuki1, Mika K Kaneko1
1Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
Monoclonal antibodies in immunodiagnosis and immunotherapy
|October 12, 2023
概括
研究人员开发了一种特定的单克隆抗体B4Mab-7,用于检测EphB4蛋白. 这种抗体通过识别EphB4过度表达来诊断乳腺癌和胃癌是有价值的,有助于预测预后.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 产生红素的肝细胞癌 (Eph) 受体,特别是EphB4,是显著的受体氨酸激酶家族.
- 埃弗B4在胚胎发生过程中起着至关重要的作用,在各种癌症中病理过度表达,与预后不佳相关.
研究的目的:
- 开发针对EphB4的特定单克隆抗体 (mAbs),以预测乳腺癌和胃癌等EphB4过度表达的瘤的预后.
- 建立适合多种应用的抗EphB4 mAb,包括流细胞计,西斑和免疫组织化学 (IHC).
主要方法:
- 利用基于细胞的免疫和查产生抗EphB4 mAbs.
- 接种了EphB4过度表达的中国仓鼠卵巢 (CHO) -K1细胞的免疫小鼠.
- 通过流式细胞计量,西部斑块和IHC. 建立并验证了B4Mab-7 mAb.
主要成果:
- 成功生成了抗EphB4 mAb克隆B4Mab-7.
- B4Mab-7通过在MCF-7乳腺癌细胞中与内源的EphB4反应而不是在EphB4-淘汰赛细胞中表现出特异性.
- 在两种细胞系中确定了B4Mab-7对EphB4的高亲和力 (低KD值).
- 证实了B4Mab-7在检测西部斑块中的EphB4蛋白和通过IHC染色瘤组织中的实用性.
结论:
- B4Mab-7 mAb是一种高度特定和多功能工具,用于检测EphB4.
- 这种抗体在乳腺癌,胃癌和其他过度表达EphB4的癌症中具有显著的预后应用潜力.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
167
相关概念视频
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:31Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K